Clinical Trials Using Cabozantinib S-malate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cabozantinib S-malate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 27
1 2 Next >

  • Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients with Locally Advanced or Metastatic Kidney Cancer

    This randomized phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving cabozantinib s-malate, crizotinib, or savolitinib will work better in treating patients with kidney cancer compared to sunitinib malate.
    Location: 508 locations

  • Cabozantinib S-malate in Treating Patients with Neuroendocrine Tumors Previously Treated with Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

    This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
    Location: 299 locations

  • Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

    This phase II trial studies how well the combination of cabozantinib, nivolumab, and ipilimumab work in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination of cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
    Location: 155 locations

  • Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

    This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.
    Location: 131 locations

  • Cabozantinib S-malate and Nivolumab in Treating Patients with Advanced, Recurrent or Metastatic Endometrial Cancer

    This randomized phase II trial studies how well cabozantinib s-malate and nivolumab work in treating patients with endometrial that has come back or spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may work better in treating endometrial cancer.
    Location: 33 locations

  • Cabozantinib S-Malate in Treating Patients with Advanced Solid Tumors and Human Immunodeficiency Virus

    This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and human immunodeficiency virus. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 18 locations

  • Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer and gastroesophageal junction cancer (GC / GEJC), colorectal cancer (CRC), head and neck (H&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Two exploratory single-agent cabozantinib (SAC) cohorts will also be enrolled with UC or NSCLC subjects.
    Location: 19 locations

  • Cabozantinib S-malate in Treating Patients with Plexiform Neurofibromas or Neurofibromatosis Type 1

    This phase II trial studies how well cabozantinib S-malate works in treating patients with plexiform neurofibromas or neurofibromatosis type 1. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 12 locations

  • Cabozantinib-S-Malate and Panitumumab in Treating Patients with Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

    This phase Ib / II trial studies the safety and best dose of cabozantinib-s-malate when given together with panitumumab in treating patients with colorectal cancer that has spread to other parts of the body or cannot be removed by surgery. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread Giving cabozantinib-s-malate with panitumumab may work better in treating patients with colorectal cancer.
    Location: 8 locations

  • Nivolumab and Cabozantinib S-malate in Treating Patients with Advanced or Metastatic Kidney Cancer

    This phase II trial studies how well nivolumab and cabozantinib s-malate work in treating patients with kidney cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and cabozantinib s-malate may work better in treating patients with advanced or metastatic kidney cancer.
    Location: 7 locations

  • A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

    The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
    Location: 8 locations

  • Cabozantinib-s-malate in Treating Patients with Non-small Cell Lung Cancer That Is Metastatic or Cannot Be Removed by Surgery

    This phase II trial studies how well cabozantinib-s-malate works in treating patients with non-small cell lung cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 7 locations

  • Cabozantinib S-malate and Cetuximab in Treating Patients with Metastatic Head and Neck Squamous Cell Cancer

    This phase I trial studies the side effects and best dose of cabozantinib S-malate and when given together with cetuximab in treating patients with head and neck squamous cell cancer that has spread to other places in the body. Cabozantinib S-malate may slow the growth of cancer cells by cutting off the blood supply that the cancer needs to survive and grow. Immunotherapy with monoclonal antibodies, such as cetuximab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib S-malate and cetuximab may work better in treating patients with head and neck cancer.
    Location: 6 locations

  • Cabozantinib-s-malate and Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Genitourinary Tumors

    This phase I trial studies the side effects and best doses of cabozantinib-s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread to other places in the body. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib-s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.
    Location: 8 locations

  • Pembrolizumab and Cabozantinib S-malate in Treating Patients with Locally Advanced, Recurrent, or Metastatic Kidney Cancer

    This phase I / II trial studies how well cabozantinib s-malate works when given together with pembrolizumab in treating patients with kidney cancer that has come back, spread from where it started to nearby tissue or lymph nodes, or spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and cabozantinib s-malate may work better in treating patients with renal cell carcinoma.
    Location: 4 locations

  • A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy

    The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy.
    Location: 5 locations

  • Cabozantinib and Isotretinoin in Treating Children with Relapsed or Refractory Solid Tumors

    This phase I trial studies the best dose and side effects of cabozantinib when given in combination with isotretinoin in treating children with solid tumors that have come back or do not respond to treatment. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin is a drug closely related to vitamin A and it may to help stop the growth and spread of tumor cells. Giving cabozantinib and isotretinoin may work better at treating solid tumors.
    Location: 2 locations

  • Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

    This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. An exploratory arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.
    Location: 4 locations

  • Cabozantinib S-malate and Durvalumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies

    This phase Ib trial studies the side effects and best dose of cabozantinib S-malate when given together with durvalumab in treating patients with stage III-IV gastroesophageal cancer and other gastrointestinal malignancies. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib S-malate and durvalumab may work better in treating patients with gastroesophageal cancer and other gastrointestinal malignancies compared to cabozantinib or durvalumab alone.
    Location: University of Kansas Cancer Center, Kansas City, Kansas

  • Cabozantinib and Pembrolizumab as First Line Therapy in Treating Patients with Cisplatin-Ineligible Metastatic, Locally Advanced, or Unresectable Urothelial Cancer

    This phase II trial studies the side effects and best dose of cabozantinib when given together with pembrolizumab and how well it works as first line therapy in treating patients with cisplatin-ineligible urothelial cancer that has spread to nearby tissue or lymph nodes or has spread to other places in the body or cannot be removed by surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and pembrolizumab may work better in treating patients with cisplatin-ineligible metastatic, locally advanced or unresectable urothelial cancer.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Cabozantinib S-Malate and Erlotinib Hydrochloride for Patients with EGFR and C-Met Co-expressing Metastatic Pancreatic Cancer

    This phase II trial studies how well cabozantinib S-malate and erlotinib hydrochloride work in treating patients with EGFR and C-Met co-expressing pancreatic cancer that has spread to other places in the body. Cabozantinib S-malate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Cabozantinib S-malate and Avelumab in Treating Participants with Metastatic Kidney Cancer

    This phase I trial studies the side effects and best dose of cabozantinib s-malate and avelumab in treating participants with kidney cancer that has spread to other places in the body. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as avelumab may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib s-malate and avelumab may work better in treating participants with metastatic kidney cancer.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Cabozantinib S-malate in Treating Children with Recurrent or Refractory High Grade Glioma

    This phase II trial studies the side effects and how well cabozantinib S-malate works in treating children with high grade glioma that has come back or does not respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Riley Hospital for Children, Indianapolis, Indiana

  • Cabozantinib S-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

    This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body and cannot be removed by surgery. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking the growth of new blood vessels necessary for tumor growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Cabozantinib-s-malate in Treating Patients with Previously Treated Non-small Cell Lung Cancer and Brain Metastases

    This phase II trial studies how well cabozantinib-s-malate works in treating patients with previously treated non-small cell lung cancer that has spread to the brain. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania


1 2 Next >